Vivos Therapeutics Reports Promising Findings for Child OSA Treatment
Positive Clinical Trial Results for Vivos Technology
Vivos Therapeutics, Inc. (NASDAQ: VVOS), known for its pioneering work in non-invasive solutions for obstructive sleep apnea (OSA), has announced exciting findings resulting from a multi-center clinical trial published in a reputable pediatric journal. This study has shown that Vivos’ patented Daytime-Nighttime Appliance (DNA) effectively treats OSA in children.
Safety and Efficacy of the Vivos DNA Appliance
The published trial marks a significant milestone, as it is the first study confirming the safety and effectiveness of the Vivos DNA device in pediatric patients suffering from OSA. Not only did this device achieve FDA 510(k) clearance in the prior year for its use with moderate to severe pediatric OSA cases, but emerging data also reinforces its benefits and safe application.
Clinical Study Insights
In the study involving various pediatric patients, an impressive 79% showed improvement in their OSA symptoms, with over 61% demonstrating significant enhancement of 50% or more. Most strikingly, 17% resolved their OSA entirely, while 93% of participants with severe OSA experienced at least half reduction in symptoms. The study measured various acknowledged endpoints, including the Pediatric Sleep Questionnaire (PSQ) and apnea-hypopnea index (AHI). The analyzed cohort consisted of 47 children across the 12–24 month trial period.
Expert Commentary on OSA Treatment
Dr. Tammarie Heit, a co-author of the research, commented on her extensive experience treating children with Vivos products. She shared that her patients saw profound, life-altering improvements, avoiding the need for painful operations that often don’t yield lasting relief. Her support of the study’s findings aligns with her long-time advocacy for Vivos’ innovative treatment technologies.
The Urgent Issue of Pediatric OSA
Currently, an alarming 10 million children in the nation are affected by sleep disorders including OSA, with up to 90% remaining undiagnosed. Such conditions are closely linked to various health issues, including developmental disorders like ADD/ADHD, sleep disturbances like snoring, cognitive influences such as lower IQ, and even anxiety issues. These alarming correlations highlight the necessity for more accessible and effective treatments.
Challenges with Conventional Treatments
Traditional approaches mostly involve adenotonsillectomy, a common surgical procedure aiming to remove the tonsils and adenoids. Annually, over 500,000 children undergo this surgery, seeking OSA relief, but the long-term outcomes can be disappointing. Research shows that while many children may experience immediate relief, over half may see their symptoms return within three years.
Vivos DNA: A Game-Changer for Pediatric OSA
The latest study suggests that Vivos’ treatment may provide lasting benefits well beyond the initial trial duration. Comparatively, current treatments like continuous positive airway pressure (CPAP) therapy and rapid maxillary expansion come with multiple drawbacks, from the need for constant compliance to potential complications. Vivos’ DNA device presents a viable and innovative alternative for treating pediatric OSA effectively.
The Call for Evidence-Based Care
A recent report sheds light on the critical issues surrounding the overtreatment of children in healthcare, specifically related to adenotonsillectomy for chronic sleep issues like OSA. This pressing document emphasizes the substantial risks children face from unnecessary surgeries, advocating for safer, evidence-based treatment options. Herein lies an opportunity for Vivos’ non-invasive technology to fill the gap, offering effective solutions without severe consequences.
CEO Perspective and Future Plans
R. Kirk Huntsman, Chairman and CEO of Vivos, expressed his enthusiasm about the implications of this study for children battling OSA. He noted the importance of providing parents with alternatives to invasive surgeries that often do not yield long-lasting results. Additionally, Huntsman hinted at Vivos’ aspirations for expanding access to their innovative wellness solutions, especially following their acquisition of the Sleep Center of Nevada.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology trailblazer focused on improving sleep health through innovative treatment and diagnostic solutions for conditions like obstructive sleep apnea (OSA). Their Complete Airway Repositioning and/or Expansion (CARE) devices are the only FDA-cleared oral appliances catering to all severity levels of OSA in both adults and children. With findings highlighting the struggles faced by over one billion individuals globally suffering from OSA, Vivos is committed to addressing these pressing health challenges.
Empowering Patients Through Innovation
Founded in 2016 in Littleton, Colorado, Vivos is dedicated to enhancing healthcare provider capabilities through enhanced technology and collaboration with specialists. Their offerings focus on non-invasive, non-pharmaceutical options to provide hope and healing, allowing patients to literally breathe new life.
Frequently Asked Questions
What is the focus of Vivos Therapeutics?
Vivos Therapeutics specializes in innovative non-invasive treatments for obstructive sleep apnea (OSA) and related disorders.
What were the findings of the recent clinical trial?
The trial found that 79% of pediatric participants showed improvement in their OSA symptoms, with many experiencing significant relief.
How does the Vivos DNA appliance work?
The DNA appliance helps treat OSA by promoting natural jaw development to alleviate airway obstruction without surgeries.
Why is it essential to consider non-invasive treatments?
Non-invasive solutions reduce risks associated with surgical procedures and often provide effective relief for patients of all ages.
What are the implications of the recent report on pediatric healthcare?
The report highlights the dangers of overtreatment in children, advocating for safer, evidence-based alternatives like the Vivos DNA appliance.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.